Related Experiment Videos
[Biphosphonates in oncology]
P Khosravi Shahi1, V Díaz Muñoz de la Espada
1Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañon, Madrid. drkhosravi@hotmail.com
Anales De Medicina Interna (Madrid, Spain : 1984)
|February 4, 2006
Summary
Bisphosphonates, pyrophosphate analogues, inhibit osteoclast activity. They treat bone diseases like Paget's and osteoporosis, and manage cancer-related bone issues, despite low oral absorption and GI side effects.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Context:
- Bisphosphonates are pyrophosphate analogues with antiresorptive properties.
- Their low oral bioavailability (1-2%) and gastrointestinal side effects limit oral use in oncology.
- Established roles include Paget's disease, osteoporosis prevention, and post-transplant bone disease.
Purpose:
- To outline the mechanism of action and clinical applications of bisphosphonates.
- To highlight their specific uses in clinical oncology, including hypercalcemia and bone metastases.
- To reference American Society of Clinical Oncology (ASCO) guidelines for their oncological application.
Summary:
- Bisphosphonates inhibit osteoclast activation, reducing bone resorption.
- In oncology, they are crucial for managing hypercalcemia of malignancy and preventing/treating bone events associated with metastases.
- ASCO guidelines recommend bisphosphonates for hypercalcemia and bone events in breast cancer and multiple myeloma.
Impact:
- Bisphosphonates offer significant therapeutic benefits in managing various bone disorders.
- Their antiresorptive action is vital in palliative cancer care and bone health management.
- Adherence to guidelines ensures optimal use in treating skeletal complications of cancer.